<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MICARDIS HCT - telmisartan and hydrochlorothiazide tablet </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>Micardis<span class="Sup">®</span> HCT <br>(telmisartan and hydrochlorothiazide) <br>Tablets, 40 mg/12.5 mg <br>80 mg/12.5 mg and 80 mg/25 mg</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e1"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold"><span class="Emphasis">Prescribing Information</span></span></p>
</div>
<div class="Warning">
<a name="s1"></a><a name="section-2"></a><p></p>
<h1>WARNING: FETAL TOXICITY</h1>
<ul class="Disc">
<li><span class="Bold"><span class="Emphasis">When pregnancy is detected, discontinue MICARDIS HCT as soon as possible.</span></span></li>
<li>
<span class="Bold"><span class="Emphasis">Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus </span></span>(see <span class="Bold"><span class="Emphasis"><a href="#s30">WARNINGS, Fetal Toxicity</a></span></span>).</li>
</ul>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s3"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">MICARDIS HCT tablets are a combination of telmisartan, an orally active angiotensin II antagonist acting on the AT<span class="Sub">1</span> receptor subtype, and hydrochlorothiazide, a diuretic.</p>
<p>Telmisartan, a non-peptide molecule, is chemically described as 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid. Its empirical formula is C<span class="Sub">33</span>H<span class="Sub">30</span>N<span class="Sub">4</span>O<span class="Sub">2</span>, its molecular weight is 514.63, and its structural formula is:</p>
<p><a name="f1"></a><img alt="Telmisartan structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=539cdfb4-b920-48fb-8176-fe23841e3d32&amp;name=micardis%20HCT-struc01.jpg"></p>
<p>Telmisartan is a white to slightly yellowish solid. It is practically insoluble in water and in the pH range of 3 to 9, sparingly soluble in strong acid (except insoluble in hydrochloric acid), and soluble in strong base.</p>
<p>Hydrochlorothiazide is a white, or practically white, practically odorless, crystalline powder with a molecular weight of 297.74. It is slightly soluble in water, and freely soluble in sodium hydroxide solution. Hydrochlorothiazide is chemically described as 6-chloro-3,4-dihydro-2<span class="Italics"><span class="Emphasis">H</span></span>-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Its empirical formula is C<span class="Sub">7</span>H<span class="Sub">8</span>ClN<span class="Sub">3</span>O<span class="Sub">4</span>S<span class="Sub">2</span>, and its structural formula is:</p>
<p><a name="f2"></a><img alt="Telmisartan structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=539cdfb4-b920-48fb-8176-fe23841e3d32&amp;name=micardis%20HCT-struc02.jpg"></p>
<p>MICARDIS HCT tablets are formulated for oral administration in three combinations of 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 mg/25 mg telmisartan and hydrochlorothiazide, respectively. The tablets contain the following inactive ingredients: sodium hydroxide, meglumine, povidone, sorbitol, magnesium stearate, lactose monohydrate, microcrystalline cellulose, maize starch, sodium starch glycolate. As coloring agents, the 40 mg/12.5 mg and 80 mg/12.5 mg tablets contain ferric oxide red, and the 80 mg/25 mg tablets contain ferric oxide yellow. Micardis® HCT (telmisartan and hydrochlorothiazide) tablets are hygroscopic and require protection from moisture.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s4"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT<span class="Sub">1</span> receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Its action is therefore independent of the pathways for angiotensin II synthesis.</p>
<p>There is also an AT<span class="Sub">2</span> receptor found in many tissues, but AT<span class="Sub">2</span> is not known to be associated with cardiovascular homeostasis. Telmisartan has much greater affinity (&gt;3,000 fold) for the AT<span class="Sub">1</span> receptor than for the AT<span class="Sub">2</span> receptor.</p>
<p>Blockade of the renin-angiotensin system with ACE inhibitors, which inhibit the biosynthesis of angiotensin II from angiotensin I, is widely used in the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. ACE inhibitors also inhibit the degradation of bradykinin, a reaction also catalyzed by ACE. Because telmisartan does not inhibit ACE (kininase II), it does not affect the response to bradykinin. Whether this difference has clinical relevance is not yet known. Telmisartan does not bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.</p>
<p>Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of telmisartan on blood pressure.</p>
<p>Hydrochlorothiazide is a thiazide diuretic. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium salt and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin II, so coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with these diuretics.</p>
<p>The mechanism of the antihypertensive effect of thiazides is not fully understood.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-3.2.1"></a><p></p>
<h3><span class="Bold Italics">General</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-3.2.1.1"></a><p></p>
<h4>Telmisartan</h4>
<p class="First">Following oral administration, peak concentrations (C<span class="Sub">max</span>) of telmisartan are reached in 0.5-1 hour after dosing. Food slightly reduces the bioavailability of telmisartan, with a reduction in the area under the plasma concentration-time curve (AUC) of about 6% with the 40 mg tablet and about 20% after a 160 mg dose. The absolute bioavailability of telmisartan is dose dependent. At 40 and 160 mg the bioavailability was 42% and 58%, respectively. The pharmacokinetics of orally administered telmisartan are nonlinear over the dose range 20-160 mg, with greater than proportional increases of plasma concentrations (C<span class="Sub">max</span> and AUC) with increasing doses. Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours. Trough plasma concentrations of telmisartan with once daily dosing are about 10-25% of peak plasma concentrations. Telmisartan has an accumulation index in plasma of 1.5 to 2.0 upon repeated once daily dosing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-3.2.1.2"></a><p></p>
<h4>Hydrochlorothiazide</h4>
<p class="First">When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-3.2.2"></a><p></p>
<h3><span class="Bold Italics">Metabolism and Elimination</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-3.2.2.1"></a><p></p>
<h4>Telmisartan</h4>
<p class="First">Following either intravenous or oral administration of <span class="Sup">14</span>C-labeled telmisartan, most of the administered dose (&gt;97%) was eliminated unchanged in feces via biliary excretion; only minute amounts were found in the urine (0.91% and 0.49% of total radioactivity, respectively).</p>
<p>Telmisartan is metabolized by conjugation to form a pharmacologically inactive acylglucuronide; the glucuronide of the parent compound is the only metabolite that has been identified in human plasma and urine. After a single dose, the glucuronide represents approximately 11% of the measured radioactivity in plasma. The cytochrome P450 isoenzymes are not involved in the metabolism of telmisartan.</p>
<p>Total plasma clearance of telmisartan is &gt;800 mL/min. Terminal half-life and total clearance appear to be independent of dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-3.2.2.2"></a><p></p>
<h4>Hydrochlorothiazide</h4>
<p class="First">Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. At least 61% of the oral dose is eliminated as unchanged drug within 24 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-3.2.3"></a><p></p>
<h3><span class="Bold Italics">Distribution</span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-3.2.3.1"></a><p></p>
<h4>Telmisartan</h4>
<p class="First">Telmisartan is highly bound to plasma proteins (&gt;99.5%), mainly albumin and α<span class="Sub">1</span>-acid glycoprotein. Plasma protein binding is constant over the concentration range achieved with recommended doses. The volume of distribution for telmisartan is approximately 500 liters, indicating additional tissue binding.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-3.2.3.2"></a><p></p>
<h4>Hydrochlorothiazide</h4>
<p class="First">Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-3.3"></a><p></p>
<h2>Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-3.3.1"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="Emphasis">Pediatric</span></span>: Telmisartan pharmacokinetics have not been investigated in patients &lt;18 years of age.</p>
<p><span class="Bold Italics"><span class="Emphasis">Geriatric</span></span>: The pharmacokinetics of telmisartan do not differ between the elderly and those younger than 65 years (see <span class="Bold"><span class="Emphasis"><a href="#s69">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-3.3.2"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="Emphasis">Gender</span></span>: Plasma concentrations of telmisartan are generally 2-3 times higher in females than in males. In clinical trials, however, no significant increases in blood pressure response or in the incidence of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> were found in women. No dosage adjustment is necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-3.3.3"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></span></span>: Renal excretion does not contribute to the clearance of telmisartan. Based on modest experience in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance of 30-80 mL/min, mean clearance approximately 50 mL/min), no dosage adjustment is necessary in patients with decreased renal function. Telmisartan is not removed from blood by hemofiltration (see <span class="Bold"><span class="Emphasis"><a href="#s37">PRECAUTIONS</a></span></span> and <span class="Bold"><span class="Emphasis"><a href="#s69">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s20"></a><a name="section-3.3.4"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span></span>: In patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, plasma concentrations of telmisartan are increased, and absolute bioavailability approaches 100% (see <span class="Bold"><span class="Emphasis"><a href="#s37">PRECAUTIONS</a></span></span> and <span class="Bold"><span class="Emphasis"><a href="#s69">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s21"></a><a name="section-3.4"></a><p></p>
<p class="First"><span class="Bold"><span class="Emphasis">Drug Interactions</span></span>: See <span class="Bold"><span class="Emphasis"><a href="#s50">PRECAUTIONS, Drug Interactions</a></span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-3.5"></a><p></p>
<h2>Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-3.5.1"></a><p></p>
<h3><span class="Bold Italics">Telmisartan</span></h3>
<p class="First">In normal volunteers, a dose of telmisartan 80 mg inhibited the pressor response to an intravenous infusion of angiotensin II by about 90% at peak plasma concentrations with approximately 40% inhibition persisting for 24 hours.</p>
<p>Plasma concentration of angiotensin II and plasma renin activity (PRA) increased in a dose-dependent manner after single administration of telmisartan to healthy subjects and repeated administration to hypertensive patients. The once-daily administration of up to 80 mg telmisartan to healthy subjects did not influence plasma aldosterone concentrations. In multiple dose studies with hypertensive patients, there were no clinically significant changes in electrolytes (serum potassium or sodium), or in metabolic function (including serum levels of <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, triglycerides, HDL, LDL, glucose, or uric acid).</p>
<p>In 30 hypertensive patients with normal renal function treated for 8 weeks with telmisartan 80 mg or telmisartan 80 mg in combination with hydrochlorothiazide 12.5 mg, there were no clinically significant changes from baseline in renal blood flow, glomerular filtration rate, filtration fraction, renovascular resistance, or creatinine clearance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-3.5.2"></a><p></p>
<h3><span class="Bold Italics">Hydrochlorothiazide</span></h3>
<p class="First">After oral administration of hydrochlorothiazide, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s25"></a><a name="section-3.6"></a><p></p>
<h2>Clinical Trials</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-3.6.1"></a><p></p>
<h3><span class="Bold Italics">Telmisartan</span></h3>
<p class="First">The antihypertensive effects of telmisartan have been demonstrated in six principal placebo-controlled clinical trials, studying a range of 20-160 mg; one of these examined the antihypertensive effects of telmisartan and hydrochlorothiazide in combination. The studies involved a total of 1773 patients with mild to moderate <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (diastolic blood pressure of 95-114 mmHg), 1031 of whom were treated with telmisartan. Following once daily administration of telmisartan, the magnitude of blood pressure reduction from baseline after placebo subtraction was approximately (SBP/DBP) 6-8/6 mmHg for 20 mg, 9-13/6-8 mmHg for 40 mg, and 12-13/7-8 mmHg for 80 mg. Larger doses (up to 160 mg) did not appear to cause a further decrease in blood pressure.</p>
<p>Upon initiation of antihypertensive treatment with telmisartan, blood pressure was reduced after the first dose, with a maximal reduction by about 4 weeks. With cessation of treatment with telmisartan tablets, blood pressure gradually returned to baseline values over a period of several days to one week. During long-term studies (without placebo control) the effect of telmisartan appeared to be maintained for up to at least one year. The antihypertensive effect of telmisartan is not influenced by patient age, gender, weight or body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index. Blood pressure response in black patients (usually a low-renin population) is noticeably less than that in Caucasian patients. This has been true for most, but not all, angiotensin II antagonists and ACE inhibitors.</p>
<p>The onset of antihypertensive activity occurs within 3 hours after administration of a single oral dose. At doses of 20, 40, and 80 mg, the antihypertensive effect of once daily administration of telmisartan is maintained for the full 24-hour dose interval. With automated ambulatory blood pressure monitoring and conventional blood pressure measurements, the 24-hour trough-to-peak ratio for 40-80 mg doses of telmisartan was 70-100% for both systolic and diastolic blood pressure. The incidence of symptomatic orthostasis after the first dose in all controlled trials was low (0.04%).</p>
<p>There were no changes in the heart rate of patients treated with telmisartan in controlled trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e26"></a><a name="section-3.6.2"></a><p></p>
<h3><span class="Bold Italics">Telmisartan and Hydrochlorothiazide</span></h3>
<p class="First">In controlled clinical trials with over 2500 patients, 1017 patients were exposed to telmisartan (20 to 160 mg) and concomitant hydrochlorothiazide (6.25 to 25 mg). These trials included one factorial trial with combinations of telmisartan (20, 40, 80, 160 mg, or placebo) and hydrochlorothiazide (6.25, 12.5, 25 mg and placebo). Four other studies of at least six months duration allowed add-on of hydrochlorothiazide for patients who either were not adequately controlled on the randomized monotherapy dose or had not achieved adequate response after completing the up-titration of telmisartan.</p>
<p>The combination of telmisartan and hydrochlorothiazide resulted in additive placebo-adjusted decreases in systolic and diastolic blood pressure at trough of 16-21/9-11 mmHg for doses between 40/12.5 mg and 80/25 mg, compared to 9-13/7-8 mmHg for telmisartan 40 mg to 80 mg and 4/4 mmHg for hydrochlorothiazide 12.5 mg alone.</p>
<p>In active controlled studies, the addition of 12.5 mg hydrochlorothiazide to titrated doses of telmisartan in patients who did not achieve or maintain adequate response with telmisartan monotherapy further reduced systolic and diastolic blood pressure.</p>
<p>The antihypertensive effect was independent of age or gender.</p>
<p>There was essentially no change in heart rate in patients treated with the combination of telmisartan and hydrochlorothiazide in the placebo controlled trial.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s27"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Micardis® HCT (telmisartan and hydrochlorothiazide) tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. This fixed dose combination is not indicated for initial therapy (see <span class="Bold"><span class="Emphasis"><a href="#s69">DOSAGE AND ADMINISTRATION</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s28"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">MICARDIS HCT tablets are contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>) to telmisartan, hydrochlorothiazide, or any other component of this product (see <span class="Bold"><span class="Emphasis"><a href="http://s61">ADVERSE REACTIONS</a></span></span>).</p>
<p>Because of the hydrochlorothiazide component, this product is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to other sulfonamide-derived drugs.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s29"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-6.1"></a><p></p>
<h2>Fetal Toxicity</h2>
<p class="First"><span class="Bold"><span class="Emphasis">Pregnancy Category D</span></span></p>
<p>Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Resulting <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. When pregnancy is detected, discontinue MICARDIS HCT as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> during pregnancy is important to optimize outcomes for both mother and fetus.</p>
<p>In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> is observed, discontinue MICARDIS HCT, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to MICARDIS HCT for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (see <span class="Bold"><span class="Emphasis"><a href="#s59">PRECAUTIONS, Pediatric Use</a></span></span>).</p>
<p>No teratogenic effects were observed when telmisartan was administered to pregnant rats at oral doses of up to 50 mg/kg/day and to pregnant rabbits at oral doses up to 45 mg/kg/day. In rabbits, embryolethality associated with maternal toxicity (reduced body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and food consumption) was observed at 45 mg/kg/day [about 12 times the maximum recommended human dose (MRHD) of 80 mg on a mg/m<span class="Sup">2</span> basis]. In rats, maternally toxic (reduction in body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and food consumption) telmisartan doses of 15 mg/kg/day (about 1.9 times the MRHD on a mg/m<span class="Sup">2</span> basis), administered during late gestation and lactation, were observed to produce adverse effects in neonates, including reduced viability, low birth weight, delayed maturation, decreased <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. Telmisartan has been shown to be present in rat fetuses during late gestation and in rat milk. The no observed effect doses for developmental toxicity in rats and rabbits, 5 and 15 mg/kg/day, respectively, are about 0.64 and 3.7 times, on a mg/m<span class="Sup">2</span> basis, the maximum recommended human dose of telmisartan (80 mg/day).</p>
<p>Studies in which hydrochlorothiazide was administered to pregnant mice and rats during their periods of major organogenesis at doses up to 3000 and 1000 mg/kg/day, respectively, provided no evidence of harm to the fetus.</p>
<p>Thiazides cross the placental barrier and appear in cord blood. There is a risk of fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possibly other adverse reactions that have occurred in adults.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> in Volume-Depleted Patients</h2>
<p class="First">Initiation of antihypertensive therapy in patients whose renin-angiotensin system are activated such as patients who are intravascular volume- or sodium-depleted, e.g., in patients treated vigorously with diuretics, should only be approached cautiously. These conditions should be corrected prior to administration of Micardis® HCT (telmisartan and hydrochlorothiazide) tablets. Treatment should be started under close medical supervision (see <span class="Bold"><span class="Emphasis"><a href="#s69">DOSAGE AND ADMINISTRATION</a></span></span>). If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, the patients should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further treatment which usually can be continued without difficulty once the blood pressure has stabilized.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-6.3"></a><p></p>
<h2>Hydrochlorothiazide</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-6.3.1"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span>: Thiazide diuretics should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-6.3.2"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reaction</span></span></span>: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> to hydrochlorothiazide may occur in patients with or without a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, but are more likely in patients with such a history.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s35"></a><a name="section-6.3.3"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic Lupus Erythematosus</span></span></span>: Thiazide diuretics have been reported to cause exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36"></a><a name="section-6.3.4"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="Emphasis">Lithium Interaction</span></span>: Lithium generally should not be given with thiazides (see <span class="Bold"><span class="Emphasis"><a href="#e52">PRECAUTIONS, Drug Interactions, </a></span></span><span class="Bold Italics"><a href="#e52">Hydrochlorothiazide</a></span>,<span class="Italics"><span class="Emphasis"><a href="#e52"> Lithium</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s36b"></a><a name="section-6.3.5"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="Emphasis">Acute <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">Myopia</span> and Secondary Angle-Closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span>:</span></span> Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span> and acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Symptoms include acute onset of decreased visual acuity or <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> and typically occur within hours to weeks of drug initiation. Untreated angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> can lead to permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span>. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> may include a history of sulfonamide or <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">penicillin allergy</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s37"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s38"></a><a name="section-7.1"></a><p></p>
<h2>Serum Electrolytes</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-7.1.1"></a><p></p>
<h3><span class="Bold Italics">Telmisartan and Hydrochlorothiazide</span></h3>
<p class="First">In controlled trials using the telmisartan/hydrochlorothiazide combination treatment, no patient administered 40/12.5 mg, 80/12.5 mg or 80/25 mg had a decrease in potassium ≥1.4 mEq/L, and no patient experienced <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. No discontinuations due to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> occurred during treatment with the telmisartan/hydrochlorothiazide combination. The absence of significant changes in serum potassium levels may be due to the opposing mechanisms of action of telmisartan and hydrochlorothiazide on potassium excretion on the kidney.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-7.1.2"></a><p></p>
<h3><span class="Bold Italics">Hydrochlorothiazide</span></h3>
<p class="First">Periodic determinations of serum electrolytes to detect possible <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> should be performed at appropriate intervals. All patients receiving thiazide therapy should be observed for clinical signs of fluid or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>: <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>, and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Serum and urine electrolyte determinations are particularly important when the patient experiences excessive <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or receives parenteral fluids. Warning signs or symptoms of fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, irrespective of cause, include dryness of mouth, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, muscular <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may develop, especially with brisk <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, when severe cirrhosis is present, or after prolonged therapy.</p>
<p>Interference with adequate oral electrolyte intake will also contribute to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may cause <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span> and may also sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>).</p>
<p>Although any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>), chloride replacement may be required in the treatment of <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>.</p>
<p>Dilutional <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt except in rare instances when the <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> is life-threatening. In actual <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span>, appropriate replacement is the therapy of choice.</p>
<p><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> may occur or frank <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> may be precipitated in certain patients receiving thiazide therapy.</p>
<p>In diabetic patients dosage adjustments of insulin or oral hypoglycemic agents may be required. <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> may occur with thiazide diuretics. Thus <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> mellitus may become manifest during thiazide therapy.</p>
<p>The antihypertensive effects of the drug may be enhanced in the post sympathectomy patient.</p>
<p>If progressive <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> becomes evident consider withholding or discontinuing diuretic therapy.</p>
<p>Thiazides have been shown to increase the urinary excretion of magnesium; this may result in <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>.</p>
<p>Thiazides may decrease urinary calcium excretion. Thiazides may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> may be evidence of hidden <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span>. Thiazides should be discontinued before carrying out tests for parathyroid function.</p>
<p>Increases in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglyceride levels may be associated with thiazide diuretic therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-7.2"></a><p></p>
<h2>Impaired Hepatic Function</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-7.2.1"></a><p></p>
<h3><span class="Bold Italics">Telmisartan</span></h3>
<p class="First">As the majority of telmisartan is eliminated by biliary excretion, patients with biliary obstructive disorders or <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> can be expected to have reduced clearance. Micardis® HCT (telmisartan and hydrochlorothiazide) tablets should therefore be used with caution in these patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-7.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-7.3.1"></a><p></p>
<h3><span class="Bold Italics">Telmisartan</span></h3>
<p class="First">As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists has been associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and/or progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> and (rarely) with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Similar results may be anticipated in patients treated with telmisartan.</p>
<p>In studies of ACE inhibitors in patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, increases in serum creatinine or blood urea nitrogen were observed. There has been no long-term use of telmisartan in patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span> but an effect similar to that seen with ACE inhibitors should be anticipated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-7.3.2"></a><p></p>
<h3><span class="Bold Italics">Hydrochlorothiazide</span></h3>
<p class="First">Thiazides should be used with caution in severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. In patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, thiazides may precipitate <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>. Cumulative effects of the drug may develop in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46a"></a><a name="section-7.4"></a><p></p>
<h2>Dual Blockade of the Renin-angiotensin-aldosterone System</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s46a.1"></a><a name="section-7.4.1"></a><p></p>
<h3><span class="Bold Italics">Telmisartan</span></h3>
<p class="First">As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function (including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>) have been reported.  Dual blockade of the renin-angiotensin-aldosterone system (e.g., by adding an ACE-inhibitor to an angiotensin II receptor antagonist) should include close monitoring of renal function.</p>
<p>The ONTARGET trial enrolled 25,620 patients &gt;55 years old with atherosclerotic disease or <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with end-organ damage, randomized them to telmisartan only, ramipril only, or the combination, and followed them for a median of 56 months. Patients receiving the combination of telmisartan and ramipril did not obtain any additional benefit on the composite endpoint of cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> hospitalization compared to monotherapy, but experienced an increased incidence of clinically important renal dysfunction (e.g., <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>) compared with groups receiving telmisartan alone or ramipril alone. </p>
<p>Co-administration of telmisartan and ramipril increases the exposure to both ramipril and ramiprilat by a factor of about 2 (see <span class="Bold"><span class="Emphasis"><a href="#s37">PRECAUTIONS</a>, <a href="#s50">Drug Interactions</a></span></span>). </p>
<p>Concomitant use of telmisartan and ramipril is not recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s46"></a><a name="section-7.5"></a><p></p>
<h2>Information for Patients</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-7.5.1"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="Emphasis">Pregnancy</span></span>: Female patients of childbearing age should be told about the consequences of exposure to MICARDIS HCT during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-7.5.2"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="Emphasis">Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></span>: A patient receiving Micardis® HCT (telmisartan and hydrochlorothiazide) tablets should be cautioned that <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> can occur, especially during the first days of therapy, and that it should be reported to the prescribing physician. The patients should be told that if <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> occurs, MICARDIS HCT tablets should be discontinued until the physician has been consulted.</p>
<p>All patients should be cautioned that inadequate fluid intake, excessive perspiration, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> can lead to an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>, with the same consequences of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> and possible <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s49"></a><a name="section-7.5.3"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="Emphasis">Potassium Supplements</span></span>: A patient receiving MICARDIS HCT tablets should be told not to use potassium supplements or salt substitutes that contain potassium without consulting the prescribing physician.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s50"></a><a name="section-7.6"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-7.6.1"></a><p></p>
<h3><span class="Bold Italics">Telmisartan</span></h3>
<p class="First"><span class="Italics"><span class="Emphasis">Digoxin</span></span>: When telmisartan was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed. It is, therefore, recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing telmisartan to avoid possible over- or under-digitalization.</p>
<p><span class="Italics"><span class="Emphasis">Lithium</span></span>: Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors. Cases have also been reported with angiotensin II receptor antagonists including telmisartan. Because lithium should not be used with diuretics, the use of lithium with telmisartan and hydrochlorothiazide is not recommended.</p>
<p><span class="Italics"><span class="Emphasis">Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)</span></span>: In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including telmisartan, may result in deterioration of renal function, including possible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. These effects are usually reversible. Monitor renal function periodically in patients receiving telmisartan and NSAID therapy.</p>
<p>The antihypertensive effect of angiotensin II receptor antagonists, including telmisartan may be attenuated by NSAIDs including selective COX-2 inhibitors.</p>
<p><span class="Italics"><span class="Emphasis">Ramipril and Ramiprilat</span></span>: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state C<span class="Sub">max</span> and AUC of ramipril 2.3 and 2.1 fold, respectively, and C<span class="Sub">max</span> and AUC of ramiprilat 2.4 and 1.5 fold, respectively. In contrast, C<span class="Sub">max</span> and AUC of telmisartan decrease by 31% and 16%, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.</p>
<p><span class="Italics"><span class="Emphasis">Warfarin</span></span>: Telmisartan administered for 10 days slightly decreased the mean warfarin trough plasma concentration; this decrease did not result in a change in International Normalized Ratio (INR).</p>
<p><span class="Italics"><span class="Emphasis">Other Drugs</span></span>: Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glibenclamide, simvastatin, hydrochlorothiazide or ibuprofen. Telmisartan is not metabolized by the cytochrome P450 system and had no effects <span class="Italics"><span class="Emphasis">in vitro</span></span> on cytochrome P450 enzymes, except for some inhibition of CYP2C19. Telmisartan is not expected to interact with drugs that inhibit cytochrome P450 enzymes; it is also not expected to interact with drugs metabolized by cytochrome P450 enzymes, except for possible inhibition of the metabolism of drugs metabolized by CYP2C19.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-7.6.2"></a><p></p>
<h3><span class="Bold Italics">Hydrochlorothiazide</span></h3>
<p class="First">When administered concurrently, the following drugs may interact with thiazide diuretics:</p>
<p><span class="Italics"><span class="Emphasis">Alcohol, barbiturates, or narcotics</span></span>: Potentiation of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> may occur.</p>
<p><span class="Italics"><span class="Emphasis">Antidiabetic drugs (oral agents and insulin)</span></span>: Dosage adjustment of the antidiabetic drug may be required.</p>
<p><span class="Italics"><span class="Emphasis">Other antihypertensive drugs</span></span>: Additive effect or potentiation.</p>
<p><span class="Italics"><span class="Emphasis">Cholestyramine and colestipol resins</span></span>: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively.</p>
<p><span class="Italics"><span class="Emphasis">Corticosteroids, ACTH</span></span>: Intensified <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span>, particularly <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.</p>
<p><span class="Italics"><span class="Emphasis">Pressor amines (e.g., norepinephrine)</span></span>: Possible decreased response to pressor amines but not sufficient to preclude their use.</p>
<p><span class="Italics"><span class="Emphasis">Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine)</span></span>: Possible increased responsiveness to the muscle relaxant.</p>
<p><span class="Italics"><span class="Emphasis">Lithium</span></span>: Should not generally be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. Refer to the package insert for lithium preparations before use of such preparations with Micardis® HCT (telmisartan and hydrochlorothiazide) tablets.</p>
<p><span class="Italics"><span class="Emphasis">Non-steroidal anti-inflammatory drugs</span></span>: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when MICARDIS HCT tablets and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s53"></a><a name="section-7.7"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s54"></a><a name="section-7.7.1"></a><p></p>
<h3><span class="Bold Italics">Telmisartan and Hydrochlorothiazide</span></h3>
<p class="First">No carcinogenicity, mutagenicity, or fertility studies have been conducted with the combination of telmisartan and hydrochlorothiazide.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-7.7.2"></a><p></p>
<h3><span class="Italics">Telmisartan</span></h3>
<p class="First">There was no evidence of carcinogenicity when telmisartan was administered in the diet to mice and rats for up to 2 years. The highest doses administered to mice (1000 mg/kg/day) and rats (100 mg/kg/day) are, on a mg/m<span class="Sup">2</span> basis, about 59 and 13 times, respectively, the maximum recommended human dose (MRHD) of telmisartan. These same doses have been shown to provide average systemic exposures to telmisartan &gt;100 times and &gt;25 times, respectively, the systemic exposure in humans receiving the MRHD (80 mg/day).</p>
<p>Genotoxicity assays did not reveal any telmisartan-related effects at either the gene or chromosome level. These assays included bacterial mutagenicity tests with <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span></span> and <span class="Italics"><span class="Emphasis">E. coli</span></span> (Ames), a gene mutation test with Chinese hamster V79 cells, a cytogenetic test with human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, and a mouse micronucleus test.</p>
<p>No drug-related effects on the reproductive performance of male and female rats were noted at 100 mg/kg/day (the highest dose administered), about 13 times, on a mg/m<span class="Sup">2</span> basis, the MRHD of telmisartan. This dose in the rat resulted in an average systemic exposure (telmisartan AUC as determined on day 6 of pregnancy) at least 50 times the average systemic exposure in humans at the MRHD (80 mg/day).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s56"></a><a name="section-7.7.3"></a><p></p>
<h3><span class="Italics">Hydrochlorothiazide</span></h3>
<p class="First">Two-year feeding studies in mice and rats conducted under the auspices of the National Toxicology Program (NTP) uncovered no evidence of a carcinogenic potential of hydrochlorothiazide in female mice (at doses of up to approximately 600 mg/kg/day) or in male and female rats (at doses of up to approximately 100 mg/kg/day). The NTP, however, found equivocal evidence for hepatocarcinogenicity in male mice.</p>
<p>Hydrochlorothiazide was not genotoxic <span class="Italics"><span class="Emphasis">in vitro</span></span> in the Ames mutagenicity assay of <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span></span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA 98, TA 100, TA 1535, TA 1537, and TA 1538 and in the Chinese Hamster Ovary (CHO) test for chromosomal aberrations, or <span class="Italics"><span class="Emphasis">in vivo</span></span> in assays using mouse germinal cell chromosomes, Chinese hamster bone marrow chromosomes, and the <span class="Italics"><span class="Emphasis">Drosophila</span></span> sex-linked recessive lethal trait gene. Positive test results were obtained in the <span class="Italics"><span class="Emphasis">in vitro</span></span> CHO Sister Chromatid Exchange (clastogenicity) assay, in the Mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> Cell (mutagenicity) assay, and in the <span class="Italics"><span class="Emphasis">Aspergillus nidulans</span></span> non-disjunction assay.</p>
<p>Hydrochlorothiazide had no adverse effects on the fertility of mice and rats of either sex in studies wherein these species were exposed, via their diet, to doses of up to 100 and 4 mg/kg, respectively, prior to mating and throughout gestation.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s58"></a><a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether telmisartan is excreted in human milk, but telmisartan was shown to be present in the milk of lactating rats. Thiazides appear in human milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s59"></a><a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First"><span class="Underline"><span class="Emphasis">Neonates with a history of in utero exposure to MICARDIS HCT:</span></span><br>
								If <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or substituting for disordered renal function.</p>
<p>Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s60"></a><a name="section-7.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">In the controlled clinical trials (n=1017), approximately 20% of patients treated with telmisartan/hydrochlorothiazide were 65 years of age or older, and 5% were 75 years of age or older. No overall differences in effectiveness and safety of telmisartan/hydrochlorothiazide were observed in these patients compared to younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s61"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Micardis® HCT (telmisartan and hydrochlorothiazide) tablets has been evaluated for safety in over 1700 patients, including 716 treated for over six months and 420 for over one year. In clinical trials with MICARDIS HCT tablets, no unexpected adverse events have been observed. Adverse experiences have been limited to those that have been previously reported with telmisartan and/or hydrochlorothiazide. The overall incidence of adverse experiences reported with the combination was comparable to placebo. Most adverse experiences were mild in intensity and transient in nature and did not require discontinuation of therapy.</p>
<p>Adverse events occurring at an incidence of 2% or more in patients treated with telmisartan/hydrochlorothiazide and at a greater rate than in patients treated with placebo, irrespective of their causal association, are presented in <a href="#t1">Table 1</a>.</p>
<a name="t1"></a><table border="0" width="100%">
<caption><span>TABLE 1 Adverse Events Occurring in ≥ 2% of Telmisartan/Hydrochlorothiazide (HCTZ) Patients*</span></caption>
<col align="left" width="20%">
<col align="left" width="20%">
<col align="left" width="20%">
<col align="left" width="20%">
<col align="left" width="20%">
<thead>
<tr class="First Toprule">
<td align="left" valign="top"> </td>
<td align="left" valign="top">Telm/HCTZ</td>
<td align="left" valign="top">Placebo</td>
<td align="left" valign="top">Telm</td>
<td align="left" valign="top">HCTZ</td>
</tr>
<tr>
<td align="left" valign="top"> </td>
<td align="left" valign="top">(N=414)</td>
<td align="left" valign="top">(N=74)</td>
<td align="left" valign="top">(N=209)</td>
<td align="left" valign="top">(N=121)</td>
</tr>
<tr class="Last">
<td align="left" valign="top"> </td>
<td align="left" valign="top">(%)</td>
<td align="left" valign="top">(%)</td>
<td align="left" valign="top">(%)</td>
<td align="left" valign="top">(%)</td>
</tr>
</thead>
<tfoot><tr class="First Last"><td align="left" colspan="5" valign="top">* <span class="Italics"><span class="Emphasis"> includes all doses of telmisartan (20-160 mg), hydrochlorothiazide (6.25-25 mg), and combinations thereof</span></span>
</td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left" valign="top"><span class="Bold"><span class="Emphasis">Body as a whole</span></span></td>
<td align="left" valign="bottom"> </td>
<td align="left" valign="bottom"> </td>
<td align="left" valign="bottom"> </td>
<td align="left" valign="bottom"> </td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="left" valign="bottom">3</td>
<td align="left" valign="bottom">1</td>
<td align="left" valign="bottom">3</td>
<td align="left" valign="bottom">3</td>
</tr>
<tr>
<td class="Toprule" align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like<br>  symptoms</td>
<td class="Toprule" align="left" valign="bottom">2</td>
<td class="Toprule" align="left" valign="bottom">1</td>
<td class="Toprule" align="left" valign="bottom">2</td>
<td class="Toprule" align="left" valign="bottom">3</td>
</tr>
<tr>
<td class="Toprule" align="left" valign="top"><span class="Bold"><span class="Emphasis">Central/peripheral nervous system</span></span></td>
<td class="Toprule" align="left" valign="bottom"> </td>
<td class="Toprule" align="left" valign="bottom"> </td>
<td class="Toprule" align="left" valign="bottom"> </td>
<td class="Toprule" align="left" valign="bottom"> </td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="left" valign="bottom">5</td>
<td align="left" valign="bottom">1</td>
<td align="left" valign="bottom">4</td>
<td align="left" valign="bottom">6</td>
</tr>
<tr>
<td class="Toprule" align="left" valign="top"><span class="Bold"><span class="Emphasis">Gastrointestinal system</span></span></td>
<td class="Toprule" align="left" valign="bottom"> </td>
<td class="Toprule" align="left" valign="bottom"> </td>
<td class="Toprule" align="left" valign="bottom"> </td>
<td class="Toprule" align="left" valign="bottom"> </td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="left" valign="bottom">3</td>
<td align="left" valign="bottom">0</td>
<td align="left" valign="bottom">5</td>
<td align="left" valign="bottom">2</td>
</tr>
<tr>
<td class="Toprule" align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Toprule" align="left" valign="bottom">2</td>
<td class="Toprule" align="left" valign="bottom">0</td>
<td class="Toprule" align="left" valign="bottom">1</td>
<td class="Toprule" align="left" valign="bottom">2</td>
</tr>
<tr>
<td class="Toprule" align="left" valign="top"><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory system disorder</span></span></span></td>
<td class="Toprule" align="left" valign="bottom"> </td>
<td class="Toprule" align="left" valign="bottom"> </td>
<td class="Toprule" align="left" valign="bottom"> </td>
<td class="Toprule" align="left" valign="bottom"> </td>
</tr>
<tr>
<td align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td align="left" valign="bottom">4</td>
<td align="left" valign="bottom">3</td>
<td align="left" valign="bottom">3</td>
<td align="left" valign="bottom">6</td>
</tr>
<tr class="Last">
<td class="Toprule" align="left" valign="top">  Upper respiratory<br>
									  tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></td>
<td class="Toprule" align="left" valign="bottom">8</td>
<td class="Toprule" align="left" valign="bottom">7</td>
<td class="Toprule" align="left" valign="bottom">7</td>
<td class="Toprule" align="left" valign="bottom">10</td>
</tr>
</tbody>
</table>
<p>The following adverse events were reported at a rate less than 2% in patients treated with telmisartan/hydrochlorothiazide and at a greater rate than in patients treated with placebo: <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">hypotension postural</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>.</p>
<p>Finally, the following adverse events were reported at a rate of 2% or greater in patients treated with telmisartan/hydrochlorothiazide, but were as, or more common in the placebo group: <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>.</p>
<p>Adverse events occurred at approximately the same rates in men and women, older and younger patients, and black and non-black patients.</p>
<p>In controlled trials (n=1017), 0.3% of patients treated with Micardis® HCT (telmisartan and hydrochlorothiazide) tablets 40/12.5 mg, 80/12.5 mg or 80/25 mg discontinued due to <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, and the incidence of <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> was 4%, 7%, and 1%, respectively.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s62"></a><a name="section-8.1"></a><p></p>
<h2>Telmisartan</h2>
<p class="First">Other adverse experiences that have been reported with telmisartan, without regard to causality, are listed below:</p>
<p><span class="Bold Italics"><span class="Emphasis">Autonomic Nervous System</span></span>: <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span></p>
<p><span class="Bold Italics"><span class="Emphasis">Body as a Whole</span></span>: <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">leg pain</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span></p>
<p><span class="Bold Italics"><span class="Emphasis">Cardiovascular</span></span>: <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">dependent edema</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">leg edema</span>, <span class="product-label-link" type="condition" conceptid="320536" conceptname="Electrocardiogram abnormal">abnormal ECG</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span></p>
<p><span class="Bold Italics"><span class="Emphasis">CNS</span></span>: <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, involuntary muscle contractions, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoaesthesia</span></p>
<p><span class="Bold Italics"><span class="Emphasis">Gastrointestinal</span></span>: <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span>, <span class="product-label-link" type="condition" conceptid="4099176" conceptname="Toothache">toothache</span>, non-specific <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span></p>
<p><span class="Bold Italics"><span class="Emphasis">Metabolic</span></span>: <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">hypercholesterolemia</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus</p>
<p><span class="Bold Italics"><span class="Emphasis">Musculoskeletal</span></span>: <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span></p>
<p><span class="Bold Italics"><span class="Emphasis">Psychiatric</span></span>: <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span></p>
<p><span class="Bold Italics"><span class="Emphasis">Resistance Mechanism</span></span>: <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span></p>
<p><span class="Bold Italics"><span class="Emphasis">Respiratory</span></span>: <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span></p>
<p><span class="Bold Italics"><span class="Emphasis">Skin</span></span>: <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p>
<p><span class="Bold Italics"><span class="Emphasis">Urinary</span></span>: micturition frequency, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span></p>
<p><span class="Bold Italics"><span class="Emphasis">Vascular</span></span>: <span class="product-label-link" type="condition" conceptid="434056" conceptname="Late effects of cerebrovascular disease">cerebrovascular disorder</span></p>
<p><span class="Bold Italics"><span class="Emphasis">Special Senses</span></span>: <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">earache</span></p>
<p>A single case of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> was reported (among a total of 3781 patients treated with telmisartan).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s64"></a><a name="section-8.2"></a><p></p>
<h2>Hydrochlorothiazide</h2>
<p class="First">Other adverse experiences that have been reported with hydrochlorothiazide, without regard to causality, are listed below:</p>
<p><span class="Bold Italics"><span class="Emphasis">Body as a whole</span></span>: <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span></p>
<p><span class="Bold Italics"><span class="Emphasis">Digestive</span></span>: <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (intrahepatic <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>), <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span>, cramping, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span></p>
<p><span class="Bold Italics"><span class="Emphasis">Hematologic</span></span>: <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> </p>
<p><span class="Bold Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></span></span>: <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span> (<span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> and <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span></p>
<p><span class="Bold Italics"><span class="Emphasis">Metabolic</span></span>: <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span></p>
<p><span class="Bold Italics"><span class="Emphasis">Musculoskeletal</span></span>: <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span></p>
<p><span class="Bold Italics"><span class="Emphasis">Nervous System/Psychiatric</span></span>: <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span></p>
<p><span class="Bold Italics"><span class="Emphasis">Renal</span></span>: <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, renal dysfunction, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span></p>
<p><span class="Bold Italics"><span class="Emphasis">Skin</span></span>: <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span></p>
<p><span class="Bold Italics"><span class="Emphasis">Special Senses</span></span>: transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s63"></a><a name="section-8.3"></a><p></p>
<h2>Post-Marketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of Micardis® (telmisartan) tablets.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure.  Decisions to include these reactions in labeling are typically based on one or more of the following factors:  (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to MICARDIS tablets.  The most frequently spontaneously reported events include:  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, lower limb <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">blood pressure increased</span>, <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">hypertension aggravated</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (including <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>), <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span> (including <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>), <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4148593" conceptname="Blood urate raised">uric acid increased</span>, abnormal hepatic function/<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">liver disorder</span>, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, increased CPK, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="4068332" conceptname="Tenalgia">tendon pain</span> (including <span class="product-label-link" type="condition" conceptid="77081" conceptname="Tibialis tendinitis">tendonitis</span>, <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">tenosynovitis</span>), <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug eruption</span> (<span class="product-label-link" type="condition" conceptid="141370" conceptname="Toxic erythema">toxic skin eruption</span> mostly reported as <span class="product-label-link" type="condition" conceptid="141370" conceptname="Toxic erythema">toxicoderma</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>), <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (in diabetic patients), and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (with fatal outcome).</p>
<p>Rare cases of <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported in patients receiving angiotensin II receptor blockers, including MICARDIS tablets.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s65"></a><a name="section-8.4"></a><p></p>
<h2>Clinical Laboratory Findings</h2>
<p class="First">In controlled trials, clinically relevant changes in standard laboratory test parameters were rarely associated with administration of Micardis® HCT (telmisartan and hydrochlorothiazide) tablets.</p>
<p><span class="Bold Italics"><span class="Emphasis">Hemoglobin and Hematocrit</span></span>: Decreases in hemoglobin (≥ 2 g/dL) and hematocrit (≥ 9%) were observed in 1.2% and 0.6% of telmisartan/hydrochlorothiazide patients, respectively, in controlled trials. Changes in hemoglobin and hematocrit were not considered clinically significant and there were no discontinuations due to <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
<p><span class="Bold Italics"><span class="Emphasis">Creatinine, Blood Urea Nitrogen (BUN)</span></span>: Increases in BUN (≥ 11.2 mg/dL) and serum creatinine (≥ 0.5 mg/dL) were observed in 2.8% and 1.4%, respectively, of patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> treated with MICARDIS HCT tablets in controlled trials. No patient discontinued treatment with MICARDIS HCT tablets due to an increase in BUN or creatinine.</p>
<p><span class="Bold Italics"><span class="Emphasis">Liver Function Tests</span></span>: Occasional elevations of liver enzymes and/or serum bilirubin have occurred. No telmisartan/hydrochlorothiazide treated patients discontinued therapy due to abnormal hepatic function.</p>
<p><span class="Bold Italics"><span class="Emphasis">Serum Electrolytes</span></span>: See <span class="Bold"><span class="Emphasis"><a href="#s37">PRECAUTIONS</a></span></span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s66"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s67"></a><a name="section-9.1"></a><p></p>
<h2>Telmisartan</h2>
<p class="First">Limited data are available with regard to overdosage in humans. The most likely manifestations of overdosage with telmisartan would be <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>; <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> could occur from parasympathetic (vagal) stimulation. If symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> should occur, supportive treatment should be instituted. Telmisartan is not removed by hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s68"></a><a name="section-9.2"></a><p></p>
<h2>Hydrochlorothiazide</h2>
<p class="First">The most common signs and symptoms observed in patients are those caused by <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span> (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>) and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> resulting from excessive <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>. If digitalis has also been administered, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> may accentuate <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>. The degree to which hydrochlorothiazide is removed by hemodialysis has not been established. The oral LD<span class="Sub">50</span> of hydrochlorothiazide is greater than 10 g/kg in both mice and rats.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s69"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The usual starting dose of telmisartan is 40 mg once a day; blood pressure response is dose related over the range of 20-80 mg. Patients with depletion of intravascular volume should have the condition corrected or telmisartan tablets should be initiated under close medical supervision (see <span class="Bold"><span class="Emphasis"><a href="#s31">WARNINGS, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> in Volume-Depleted Patients</a></span></span>). Patients with biliary obstructive disorders or <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> should have treatment started under close medical supervision (see <span class="Bold"><span class="Emphasis"><a href="#s37">PRECAUTIONS</a></span></span>).</p>
<p>Hydrochlorothiazide is effective in doses of 12.5 mg to 50 mg once daily.</p>
<p>To minimize dose-independent side effects, it is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapy. The side effects (see <span class="Bold"><span class="Emphasis"><a href="#s29">WARNINGS</a></span></span>) of telmisartan are generally rare and apparently independent of dose; those of hydrochlorothiazide are a mixture of dose-dependent phenomena (primarily <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>) and dose-independent phenomena (e.g., <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>), the former much more common than the latter. Therapy with any combination of telmisartan and hydrochlorothiazide will be associated with both sets of dose-independent side effects.</p>
<p>Micardis® HCT (telmisartan and hydrochlorothiazide) tablets may be administered with other antihypertensive agents.</p>
<p>MICARDIS HCT tablets may be administered with or without food.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s70"></a><a name="section-10.1"></a><p></p>
<h2>Replacement Therapy</h2>
<p class="First">The combination may be substituted for the titrated components.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s71"></a><a name="section-10.2"></a><p></p>
<h2>Dose Titration by Clinical Effect</h2>
<p class="First">MICARDIS HCT tablets are available as tablets containing either telmisartan 40 mg and hydrochlorothiazide 12.5 mg, or telmisartan 80 mg and hydrochlorothiazide 12.5 mg or 25 mg. A patient whose blood pressure is not adequately controlled with telmisartan monotherapy 80 mg (see above) may be switched to MICARDIS HCT tablets, telmisartan 80 mg/hydrochlorothiazide 12.5 mg once daily, and finally titrated up to 160/25 mg, if necessary.</p>
<p>A patient whose blood pressure is inadequately controlled by 25 mg once daily of hydrochlorothiazide may be switched to MICARDIS HCT (telmisartan 80 mg/hydrochlorothiazide 12.5 mg or telmisartan 80 mg/hydrochlorothiazide 25 mg) tablets once daily. The clinical response to MICARDIS HCT tablets should be subsequently evaluated and if blood pressure remains uncontrolled after 2-4 weeks of therapy, the dose may be titrated up to 160/25 mg, if necessary. Those patients controlled by 25 mg hydrochlorothiazide but who experience <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> with this regimen, may be switched to MICARDIS HCT (telmisartan 80 mg/hydrochlorothiazide 12.5 mg) tablets once daily, reducing the dose of hydrochlorothiazide without reducing the overall expected antihypertensive response.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s72"></a><a name="section-10.3"></a><p></p>
<h2>Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The usual regimens of therapy with Micardis® HCT (telmisartan and hydrochlorothiazide) tablets may be followed as long as the patient’s creatinine clearance is &gt;30 mL/min.  In patients with more severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, loop diuretics are preferred to thiazides, so MICARDIS HCT tablets are not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s73"></a><a name="section-10.4"></a><p></p>
<h2>Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">MICARDIS HCT tablets are not recommended for patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Patients with biliary obstructive disorders or <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> should have treatment started under close medical supervision using the 40/12.5 mg combination (see <span class="Bold"><span class="Emphasis"><a href="#s37">PRECAUTIONS</a></span></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s74"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">MICARDIS HCT tablets are available in three strengths as biconvex two-layered, oblong-shaped, uncoated tablets in three combinations of 40 mg/12.5 mg, 80 mg/12.5 mg and 80 mg/25 mg telmisartan and hydrochlorothiazide, respectively. The hydrochlorothiazide layer is red in the 40 mg/12.5 mg and 80 mg/12.5 mg tablets, and yellow in the 80 mg/25 mg tablets, and all are unmarked. The telmisartan layer for all three strengths is white, but may contain red specks in the 40 mg/12.5 mg and 80 mg/12.5 mg tablets and yellow specks in the 80 mg/25 mg tablets. The telmisartan layer is marked with the Boehringer Ingelheim logo and H4 for the 40 mg/12.5 mg dose strength, H8 for the 80 mg/12.5 mg dose strength and H9 for the 80 mg/25 mg dose strength.</p>
<p>Tablets are provided as follows:</p>
<p>MICARDIS HCT tablets 40 mg/12.5 mg are individually <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>-sealed in cartons of 30 tablets as 3 x 10 cards (NDC 54868-5418-0).</p>
<p>MICARDIS HCT tablets 80 mg/12.5 mg are individually <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>-sealed in cartons of 30 tablets as 3 x 10 cards (NDC 54868-4540-1), and individually <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>-sealed in cartons of 90 tablets as 9 x 10 cards (NDC 54868-4540-2).</p>
<p>MICARDIS HCT tablets 80 mg/25 mg are individually <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>-sealed in cartons of 30 tablets as 3 x 10 cards (NDC 54868-5297-0).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s75"></a><a name="section-11.1"></a><p></p>
<h2>Storage</h2>
<p class="First"><span class="Bold"><span class="Emphasis">Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F)</span></span> [see USP Controlled Room Temperature]. Tablets should not be removed from <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> until immediately before administration.</p>
<p><span class="Bold"><span class="Emphasis">Address medical inquiries to (800) 542-6257 or (800) 459-9906 TTY.</span></span></p>
<p>Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc., <br>
								Ridgefield, CT 06877 USA</p>
<p>Licensed from: Boehringer Ingelheim International GmbH, <br>
								Ingelheim, Germany</p>
<p>Copyright 2012 Boehringer Ingelheim International GmbH<br>
								ALL RIGHTS RESERVED</p>
<p>Revised: January 2012</p>
<p>IT13006NA252012<br>
								10004142/09</p>
<br><p><br></p>
<p><span class="Bold">Additional barcode labeling by:</span><br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma       74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_76"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First">Micardis HCT</p>
<p>80 mg/25 mg</p>
<p>30 Tablets</p>
<p>NDC 54868-5297-0</p>
<div class="Figure"><img alt="Micardis HCT 80 mg/25 mg 30 Tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=539cdfb4-b920-48fb-8176-fe23841e3d32&amp;name=5297.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_78"></a><a name="section-13"></a><p></p>
<h1></h1>
<p class="First">Micardis HCT</p>
<p>40 mg/12.5 mg</p>
<p>30 Tablets</p>
<p>NDC 54868-5418-0</p>
<div class="Figure"><img alt="Micardis HCT 40 mg/12.5 mg 30 Tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=539cdfb4-b920-48fb-8176-fe23841e3d32&amp;name=5418.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_80"></a><a name="section-14"></a><p></p>
<h1></h1>
<p class="First">Micardis HCT </p>
<p>80 mg/12.5 mg</p>
<p><br></p>
<p>NDC 54868-4540-2</p>
<div class="Figure"><img alt="Micardis HCT 80 mg/12.5 mg 30 Tablets" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=539cdfb4-b920-48fb-8176-fe23841e3d32&amp;name=4540.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MICARDIS HCT 		
					</strong><br><span class="contentTableReg">telmisartan and hydrochlorothiazide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5418(NDC:0597-0043)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TELMISARTAN</strong> (TELMISARTAN) </td>
<td class="formItem">TELMISARTAN</td>
<td class="formItem">40 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">12.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MEGLUMINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE) , RED (RED) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">14mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">H4;</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5418-0</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021162</td>
<td class="formItem">09/20/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MICARDIS HCT 		
					</strong><br><span class="contentTableReg">telmisartan and hydrochlorothiazide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4540(NDC:0597-0044)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TELMISARTAN</strong> (TELMISARTAN) </td>
<td class="formItem">TELMISARTAN</td>
<td class="formItem">80 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">12.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MEGLUMINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE) , RED (RED) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">H8;</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4540-1</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-4540-2</td>
<td class="formItem">9  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021162</td>
<td class="formItem">12/16/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MICARDIS HCT 		
					</strong><br><span class="contentTableReg">telmisartan and hydrochlorothiazide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5297(NDC:0597-0042)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TELMISARTAN</strong> (TELMISARTAN) </td>
<td class="formItem">TELMISARTAN</td>
<td class="formItem">80 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCHLOROTHIAZIDE</strong> (HYDROCHLOROTHIAZIDE) </td>
<td class="formItem">HYDROCHLOROTHIAZIDE</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MEGLUMINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE) , YELLOW (YELLOW) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">H9;</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5297-0</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021162</td>
<td class="formItem">06/30/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e8331ace-719a-4405-97f1-fb137e7c2444</div>
<div>Set id: 539cdfb4-b920-48fb-8176-fe23841e3d32</div>
<div>Version: 2</div>
<div>Effective Time: 20120214</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
